A comparison of low-molecular-weight and unfractionated heparin
Kate Matthews
This article has no abstract so we have provided the first paragraph of the full text.
Unfractionated heparin (UFH) has been successfully used as an antithrombin therapy for patients with ST-segment elevation myocardial infarction (STEMI); however, low-molecular-weight heparin (LMWH) has various pharmacologic and practical advantages. Sabatine and co-workers investigated whether treatment with LMWH for 48 h improved the rate of infarct-related artery patency and reduced the incidence of adverse cardiovascular events compared with UFH, and whether LMWH was safe and effective when used in combination with dual antiplatelet therapy.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mathematical physics Added dimensions to grain growthNature News and Views (26 Apr 2007)
Thrombi?beware of red cells bearing giftsNature Biotechnology News and Views (01 Aug 2003)
